{"organizations": [], "uuid": "ee0e0015a4f158e990713f8cd74392135fd8bbcb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ptc-therapeutics-receives-formal-d/brief-ptc-therapeutics-receives-formal-dispute-resolution-request-decision-idUSFWN1QA0KG", "country": "US", "domain_rank": 408, "title": "BRIEF-PTC Therapeutics Receives Formal Dispute Resolution Request Decision", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.459, "site_type": "news", "published": "2018-02-20T21:18:00.000+02:00", "replies_count": 0, "uuid": "ee0e0015a4f158e990713f8cd74392135fd8bbcb"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ptc-therapeutics-receives-formal-d/brief-ptc-therapeutics-receives-formal-dispute-resolution-request-decision-idUSFWN1QA0KG", "ord_in_thread": 0, "title": "BRIEF-PTC Therapeutics Receives Formal Dispute Resolution Request Decision", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "ptc therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "ataluren", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - PTC Therapeutics Inc:\n* PTC THERAPEUTICS RECEIVES FORMAL DISPUTE RESOLUTION REQUEST DECISION FROM THE FDA‘S OFFICE OF NEW DRUGS\n* PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS OF U.S. FDA DENIED PTC‘S APPEAL OF COMPLETE RESPONSE LETTER IN RELATION TO NDA FOR ATALUREN\n* PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS RECOMMENDED A POSSIBLE PATH FORWARD FOR ATALUREN NDA SUBMISSION BASED ON ACCELERATED APPROVAL PATHWAY\n* PTC THERAPEUTICS- LETTER FROM OFFICE OF NEW DRUGS ADDS CO‘S STUDY 041 COULD SERVE AS CONFIRMATORY POST-APPROVAL TRIAL NEEDED FOR ACCELERATED APPROVAL\n* PTC THERAPEUTICS INC - PTC CURRENTLY INTENDS TO MAINTAIN PATIENTS IN U.S. CURRENTLY RECEIVING ATALUREN FOR NMDMD Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T21:18:00.000+02:00", "crawled": "2018-02-21T21:42:20.000+02:00", "highlightTitle": ""}